Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
| ▸ | RARB | P10826 | 9/20 | 0.40 |
| ▸ | RARA | P10276 | 8/20 | 0.40 |
| ▸ | RARG | P13631 | 8/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493104 | 0.82 | POLB (0.46) | ABL1 | |
| SCHEMBL16856594 | 0.79 | L3MBTL1 (0.47) | S1PR1NPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL4798828 | 0.75 | TPH1 (0.50) | NPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL20911215 | 0.74 | NPC1 (0.48) | NR1H4S1PR1RARBRARARARG | |
| SCHEMBL4798574 | 0.74 | TP53 (0.51) | NPC1RAB9A | |
| SCHEMBL493675 | 0.74 | ALDH1A1 (0.64) | S1PR1NPC1RAB9AGAASMN1; SMN2 | |
| SCHEMBL5606878 | 0.73 | NPC1 (0.41) | S1PR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL493446 | 0.72 | ALDH1A1 (0.47) | NR1H4RARBRARARARG | |
| SCHEMBL18748548 | 0.72 | MAPK14 (0.55) | NR1H4S1PR1RARBRARARARG | |
| SCHEMBL15464553 | 0.71 | NPC1 (0.42) | NR1H4RARBRARARARGNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | NR1H4 348/4885S1PR1 2709/4885SLC9A1 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.